<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616221</url>
  </required_header>
  <id_info>
    <org_study_id>AP-PA02-201</org_study_id>
    <nct_id>NCT05616221</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection</brief_title>
  <acronym>Tailwind</acronym>
  <official_title>A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 Multi-Phage Therapeutic in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Armata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the&#xD;
      safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with&#xD;
      non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in two cohorts running in parallel: Cohort A will evaluate the&#xD;
      safety, tolerability, and efficacy of inhaled AP-PA02 in subjects who have not received an&#xD;
      antipseudomonal inhaled antibiotic for a minimum of 3 months prior. Cohort B will evaluate&#xD;
      the safety, tolerability, and efficacy of inhaled AP-PA02 in subjects who have received an&#xD;
      antipseudomonal inhaled antibiotic for a minimum of 3 months prior. Subjects in both Cohorts&#xD;
      A and B will be followed for approximately 4 weeks after last dose of study drug and&#xD;
      evaluated for safety, tolerability, and efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2023</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P. aeruginosa recovery in sputum following multiple doses of AP-PA02 administered by inhalation</measure>
    <time_frame>Day 1 pre-dose through 7 days post last dose of study drug</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-cystic Fibrosis Bronchiectasis</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <condition>Lung Infection</condition>
  <arm_group>
    <arm_group_label>AP-PA02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-pseudomonal bacteriophage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive isotonic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AP-PA02</intervention_name>
    <description>Bacteriophage administered via inhalation</description>
    <arm_group_label>AP-PA02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive Placebo administered via inhalation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Body mass index (BMI) of ≥ 18 kg/m2&#xD;
&#xD;
          -  Evidence of bronchiectasis per CT&#xD;
&#xD;
          -  Evidence of chronic pulmonary Pseudomonas aeruginosa infection&#xD;
&#xD;
          -  Willing to undergo sputum induction procedures at designated study visits, and willing&#xD;
             to provide expectorated sputum samples at all other timepoints (for subjects who are&#xD;
             able to expectorate)&#xD;
&#xD;
          -  FEV1 ≥ 35% of predicted normal [per Global Lung Function Initiative (GLI) standards]&#xD;
             at Screening&#xD;
&#xD;
          -  For Cohort A: have not received chronic inhaled antipseudomonal antibiotics regimen&#xD;
             for at least 3 months prior to Visit 1&#xD;
&#xD;
          -  For Cohort B: have received chronic inhaled antipseudomonal antibiotics regimen for at&#xD;
             least 3 months prior to Visit 1&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal vital signs at Screening&#xD;
&#xD;
          -  History of lung transplantation&#xD;
&#xD;
          -  History of cystic fibrosis&#xD;
&#xD;
          -  History of α1-antitrypsin deficiency&#xD;
&#xD;
          -  History of primary or acquired immunodeficiency syndromes&#xD;
&#xD;
          -  History of COPD&#xD;
&#xD;
          -  History of pulmonary malignancy or any other malignancy requiring treatment&#xD;
&#xD;
          -  History of prolonged QT syndrome&#xD;
&#xD;
          -  History of hemoptysis&#xD;
&#xD;
          -  Recent significant weight loss&#xD;
&#xD;
          -  Recent use of supplemental oxygen during the day while at rest&#xD;
&#xD;
          -  Recent use of cigarettes, cigars, or pipes, or used tobacco or other nicotine source&#xD;
             by vaping&#xD;
&#xD;
          -  Recent changes in either the treatment regimen or initiation of treatment with: oral&#xD;
             macrolides, hypertonic saline, mucolytics, bronchodilator medications, or oral&#xD;
             corticosteroids&#xD;
&#xD;
          -  Currently receiving treatment for active infection at any site&#xD;
&#xD;
          -  Female pregnant of breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mina Pastagia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Armata Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Kyme, PhD</last_name>
    <phone>310-665-2928</phone>
    <phone_ext>234</phone_ext>
    <email>pkyme@armatapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCONN Health</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malik Qasim</last_name>
      <email>qmalik@uchc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Metersky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Greenlee</last_name>
      <email>Kimberly.Greenlee@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela McShane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://armatapharma.com</url>
    <description>Armata Pharmaceuticals, Inc.</description>
  </link>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>January 13, 2023</last_update_submitted>
  <last_update_submitted_qc>January 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacteriophage</keyword>
  <keyword>Phage</keyword>
  <keyword>NCFB</keyword>
  <keyword>BE</keyword>
  <keyword>Pseudomonas</keyword>
  <keyword>Pseudomonas Aeruginosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

